首页 › 基金 › MPM BioImpact LLC › ANL

MPM BioImpact LLC 对 ANL 的持仓历史

ADLAI NORTYE GROUP LTD · 医疗保健

MPM BioImpact LLC 在 Q2 2026 的 13F 申报中披露持有 ANL(ADLAI NORTYE GROUP LTD)1,936,291 股,市值约 US$22.3M,约占其申报组合的 1.36%,在其申报持仓中市值排名第 27 位。 MPM BioImpact LLC 于 Q2 2026 首次申报该持仓。

最新持仓 (Q2 2026)1.94M 股
申报持仓市值$22.27M
组合权重1.36%
首次申报Q2 2026
最近变动新进
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

MPM BioImpact LLC 对 ANL 的持仓演变

MPM BioImpact LLC 于 Q2 2026 首次披露 ANL 持仓:1,936,291 股(约 US$22.3M)。

逐季持仓明细

季度股数金额变化
Q2 2026 1.94M $22.27M 新进

关于 ANL 与 13F 数据

ANL(ADLAI NORTYE GROUP LTD)属于医疗保健行业。我们追踪的基金中还有 41 只申报持有 ANL,申报仓位最大的包括:Cormorant Asset Management, LP (US$45.7M), Venrock Adviser, LLC (US$36.9M), Casdin 资本 (US$14.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 ANL 的基金

查看 ANL 的全部基金持有人 →

常见问题

How long has MPM BioImpact LLC held ANL?

MPM BioImpact LLC has disclosed ANL holdings in 1 of the last 1 reported quarters, going back to Q2 2026.

What is MPM BioImpact LLC's current position in ANL?

As of Q2 2026, MPM BioImpact LLC holds 1.94M shares of ANL (ADLAI NORTYE GROUP LTD), valued at $22.27M, representing 1.36% of its reported portfolio and ranking #27.

Has MPM BioImpact LLC been buying or selling ANL?

In the latest 13F filing (Q2 2026), MPM BioImpact LLC newly opened its position in ANL.

Which other funds hold ANL?

Other major institutional holders of ANL include Cormorant Asset Management, LP, Venrock Adviser, LLC, Casdin 资本, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.